

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/05367 A1

(51) International Patent Classification: A61K 7/48,
C09K 15/06

(21) International Application Number: PCT/BR00/00078

(22) International Filing Date: 14 July 2000 (14.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PI 9902973-1 16 July 1999 (16.07.1999) BR
PI 0003166-6 18 February 2000 (18.02.2000) BR

(71) Applicant (for all designated States except US): INDÚSTRIA E COMÉRCIO DE COSMÉTICOS NATURA LTDA. [BR/BR]; Rodovia Regis Bittencourt S/N, KM 293, CEP-06850 Itapeverica da Serra, SP (BR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ALCANTARA MARTINS ZUCCHETTI, Roberto [BR/BR]; Rua Serra do Japi, 242, Apto. 23B, Tatuapé, São Paulo, SP (BR). VILLA NOVA SILVA, Luciana [BR/BR]; Rua Americo Alves Pereira Filho, 564, Morumbi, São Paulo, SP (BR). CHITARRA SOUZA, Simoni [BR/BR]; Rua Estela, 22, Apto. 331, Paraíso, São Paulo, SP (BR). FANAN, Simone [BR/BR]; Rua Rafael Sampaio, 500, Campinas, SP (BR). GESZTESI, Jean-Luc [BR/BR]; Rua General

Jardim, 840, 5º andar, São Paulo, SP (BR). MARTINS MATHEUS, Luiz, Gustavo [BR/BR]; Rua Winston Churchill, 400, Jardim São Caetano, São Caetano do Sul, SP (BR). POMMEZ, Philippe, Joseph [CA/BR]; Rua Alceu Maynard Araújo, 433, Bl. B, apto. 21, São Paulo, SP (BR). ARAÚJO MACIAN, Karla [BR/BR]; Rua Turiassu, 161, Apto. 1002, Perdizes, São Paulo, SP (BR). FUSCELLI PYTEL, Rodrigo [BR/BR]; Rua Luperici Miranda, 1329, Bairro Campestre, Santo André, SP (BR).

(74) Agent: DANNEMANN, SIEMSEN, BIGLER & IPANEMA MOREIRA; Rua Marques de Olinda, 70, Caixa Postal 2142, CEP-22251-040 Rio de Janeiro, RJ (BR).

(81) Designated States (national): CA, JP, US.

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A PROCESS FOR STABILIZING ANTIOXIDANT COMPOUNDS, AND AQUEOUS COMPOSITIONS

(57) Abstract: The present invention is directed to a process for stabilizing antioxidant compounds comprising the step of adding to said compound, in an aqueous mean, at least an oxygen-removing compound, at least a metallic ion sequestering compound and at least an oxidation reaction reversing compound. The invention is particularly useful to stabilize antioxidant compounds such as levogyrous ascorbic acid (LAA), popularly known as "Vitamin C", and the LAA associated with proanthocyanidines (OPC) for the preparation of pharmaceutical and cosmetic compositions.

WO 01/05367 A1

THIS PAGE BLANK (USPTO)

Title: "A PROCESS FOR STABILIZING ANTIOXIDANT COMPOUNDS, AND AQUEOUS COMPOSITIONS"

Field of the Invention

5 The present invention relates to an improved process for stabilizing antioxidant compounds useful in cosmetic and pharmaceutical compositions.

Background of the Invention

10 An antioxidant compound is any compound or mixture of compounds that, when in contact with the skin, is capable of protect the skin against the action of free radicals.

15 Antioxidant compounds such as levogyrous ascorbic acid (LAA), popularly known as "Vitamin C", and proantocianidines (OPC) are widely used in the pharmaceutical and cosmetic industry since, among other characteristics, they act against the free radicals that speed up the aging process and degeneration of the cells.

20 One of the greatest technical difficulties for the use of the above antioxidant compounds is their instability. The LAA, for example, can easily be oxidized in the presence of atmospheric air, metallic ions or water, thus being transformed into dehydroascorbic acid, in addition to other by-products resulting from the oxidation. Such transformation diminishes its physiological properties, mainly under use conditions where the compound is exposed to the atmospheric air, metallic ions and water such as, for example, when incorporated into a topic solution.

25 In a simplified way, the instability of an antioxidant is expressed as a decrease of its reducing ability before it is contacted with the skin. In the case of the LAA, its instability is expressed as a compound degradation reaction.

 In the case of the OPC's the instability occurs through an oligomerization reaction, followed by polymerization.

30 The LAA is often used in the form of its salts or esters due to this instability. The compositions prepared in this way attain stability for long periods of time.

Many studies have been carried out in order to obtain an aqueous composition containing stable antioxidant compounds. Some alternatives to stabilize LAA are described in Brazilian Patent Applications PI 9704418-0 and PI 9704728-7, filed by the same applicant of the present application. In said patent applications, processes for stabilizing levogyrous ascorbic acid (LAA) in a water-containing mean are disclosed comprising the step of contacting the LAA with at least one compound capable of forming hydrogen bridges with the LAA.

Another procedure known from the art for stabilizing antioxidants involves the association thereof with the compounds capable of reverting the decomposition reaction, the so-called "reverting compounds". Once again, considering the LAA, for example, said compounds revert the dehydroascorbic acid formation reaction. However, the stabilization through this process results in compositions unacceptable for cosmetic use and many times unsuitable for medicinal use, since the required stoichiometric amount of reverting compounds within the stoichiometry limits of the reaction must be too high so that the desired results could be attained. Since the reverting compounds usually are selected from sulfur-containing compounds, the high content thereof in the resultant compositions bring about an unpleasant odor and sometimes their use are even legally forbidden. For example, in a solution containing a concentration of 5% by weight of LAA, which is a concentration range generally used in cosmetic-pharmaceutical products, contents of approximately 20% by weight of reverting compound should be required to ensure the LAA stability.

Another prior art reference that can be cited and that teaches the use of reverting compounds, is a work published by Wrinkler, B.S. (Biochim, Biophys, Acta, 1117, 1992, pages 287 through 290), in which a compound is described (Glutathion) that can act as a reducer or reverting compound of dehydroascorbic acid by transforming same into ascorbic acid in the stoichiometric form. Through this work it was discovered that it was impossible to keep stoichiometric amounts of the components to produce a cosmetic composition since the Glutathion has an unpleasant odor which is a characteristic of sulphidric compounds.

Therefore, it is an object of the present invention to provide a process for stabilizing antioxidant compounds, that is, anti-free radicals or "anti-radicals", that

makes it possible to overcome the drawbacks common to the known processes, among which the ones that use the so-called reverting compounds and, in a special way, that can result in stable, cosmetically more pleasant and more efficient compositions, also suitable for pharmaceutical use.

5 **Summary of the Invention**

The present invention is directed to a process for stabilizing antioxidant compounds comprising the step of adding to said compound, in an aqueous medium, at least one oxygen-removing compound, at least one metallic ion sequestering compound and at least one oxidation reaction reverting compound.

10 The invention is also directed to compositions containing antioxidant compounds stabilized according to the above process.

Brief Description of the Drawings

Figure 1 shows a stability graph of compositions containing LAA according to formulas prepared in accordance with the invention during at least 90
15 days at room temperature.

Figure 2 shows the stability graph of compositions containing OPC that is an oligomer of grape seed, with which it is possible to measure the stability of said OPC.

Detailed Description of the Invention

20 The present inventors have now found out that the association of at least one antioxidant compound with an oxidation reaction reverting compound, in a aqueous medium, even without fulfilling the stoichiometry limits of the oxidation reaction, together with an oxygen-removing compound and a metallic ion sequestering agent, makes it possible to stabilize said antioxidant compound.

25 For the purposes of the present invention, some definitions of the terms used herein are given below.

An oxidation reaction reverting compound, or simply reverting compound, is to be understood as any compound or mixture of compounds having a higher oxidation potential than the oxidation potential of the oxidant to be stabilized
30 so that the concentration of antioxidant sub-compounds to be generated turns back to the original antioxidant in its molecular form.

As to the oxygen-removing compound, or simply oxygen remover, is any

compound or mixture of compounds capable of decreasing the oxygen solubility in a medium containing water and the antioxidant to be stabilized.

The metallic ion sequestering, or simply sequestering agent, is any compound or mixture of compounds having a high complexing constant and being effective for capturing and retaining such ions at pH values lower than 5.0. The effectiveness of the sequestering agent is defined by its ability to complexing the metallic ions present in a medium containing water and the antioxidant to be stabilized, so that it can minimize and preferably prevents the decomposition catalysis of any antioxidant present in said medium.

The invention is particularly suitable for providing the stabilization of compositions containing antioxidant compounds such as levogyrous ascorbic acid (LAA), or proantocianidines (OPC), or both, the resultant stability being effective for long periods of time.

In a first embodiment of the invention which is related to the stabilization of LAA in a aqueous medium, the oxygen-removing compound is selected from the group consisting of glycols, more preferably among propylene glycol and butylene glycol as well as mixtures thereof, even more preferably the propylene glycol.

The metallic ion sequestering compound, on its turn, is selected from the group consisting of ethylene phosphonic acids, the salts and mixtures thereof, or from the group consisting of phosphonates including di-, tri-, tetra- and pentavalent acids, the salts and mixtures thereof. More specifically the compound capable of sequestering metallic ions can be selected from the group consisting of sodium salt of 1-hydroxy ethylidene(1,1-diphosphate) acid, ethylene diamine tetra(methylenephosphonic) acid, sodium salt of ethylene diamine tetra(methylenephosphonic) acid, diethylene diamine penta(methylenephosphonic) acid, sodium salt of diethylene diamine penta(methylene phosphonic) acid, hydroxy ethylidene(1,1-diphosphate)acid, and mixtures thereof. Preferably, 1-hydroxy ethylidene(1,1-diphosphate) acid is used as the metallic ion sequestering agent, which is commercialized under the name Dequest 2010 supplied by MONSANTO.

In accordance with a preferred embodiment of the invention, the process for stabilizing antioxidant compounds comprises a first step wherein an aqueous solution containing the oxygen-removing compound and the metallic ion

sequestering agent at a ratio ranging from 2500:1 to 50:1 is prepared. In a second step, the antioxidant compound is then added to the resultant solution in a aqueous medium.

5 In a third step, a LAA oxidation reaction reverting compound is incorporated in the solution prepared in the first step described above, at a ratio ranging from 2520:1 to 20:1 related to the total mass of the oxygen-removing compound plus the sequestering agent mass, and at a ratio ranging from 1:0,02 to 3000:1, relating to the mass of the oxidizing compound. The great advantage achieved by the present invention is the notable stability of the LAA as time goes by.

10 Compared to the compositions already known of the prior art containing this type of reverting compound, the invention allows the use of reverting compounds in significantly low amounts, thus making it possible to use same for cosmetic and/or pharmaceutical compositions, thus advantageously overcoming the aspect of unpleasant odor and the legal limitations concerning the concentration of reverting

15 compounds.

Suitable oxidation reaction reverting compounds are those conventionally known for that purpose and include sulfur-containing compounds, preferably those selected from the group consisting of sodium dithionite, bissodium disulfites, calcium dissulfites, potassium bissulfites and still more preferably

20 Glutathion, as well as mixtures thereof.

Usually, for obtaining a commercially suitable cosmetic composition containing, for example, LAA as the antioxidant agent, the latter is used in a range from about 0.01% to about 30% and preferably from about 0.5% to about 20%, by weight, while the oxygen-removing compound is used in a range from about 10% to

25 about 25%, preferably from about 16% to about 19%, and the sequestering agent is used in a range from about 0.01% to about 0.20%, preferably from about 0.10% to about 0.20%, all the percentages being by weight, based on the total weight of the composition. The oxidation reverting compound is present at a concentration from about 0.01% to about 0.5%, preferably from about 0.05% to about 0.2%. However,

30 the amounts of these components will depend on the end uses for the resultant composition and should not limit the scope of the invention.

Among the antioxidant compounds of high importance in the cosmetic

and pharmaceutical industry, the OPC's can also be cited, and they are advantageously stabilized by the process of the present invention. Regarding those OPC's that can be stabilized by the process of the invention, a more preferred embodiment of the process comprises a first step of preparing a first composition comprising the oxygen-removing compound, the sequestering agent and the oxidation reverting compound, which is then added to the OPC contained in an aqueous medium. In this preferred embodiment, the first composition contains other antioxidant, preferably the LAA.

Although the reasons are not yet fully defined, it was noticed that the presence of another antioxidant having characteristics similar to LAA in the first composition favors the stabilization of the OPC's. Without being too theoretical, it is believed that there is a synergy between the LAA present and the OPC's, resulting in an advantageously stable composition.

In a particularly advantageous way, an aqueous composition containing the stabilized antioxidant in accordance with the present invention is used in a two-phase cosmetic composition. This kind of composition comprises, in a first phase, at least one antioxidant compound, an oxygen-removing compound, a metallic ion sequestering compound and an oxidation reaction reverting compound and, in a second phase, at least one hydrating compound. Preferably, the first and second phases are used at a weight ratio between them from 12:8 to 20:11, preferably of 16:9.

The two-phase composition described above has proved to be particularly suitable for regions where the skin is more delicate and, consequently, where it requires special care. "More delicate skin" must be understood as the one more sensitive to the use of formulations that contain antioxidant compounds, emulsifying systems, fragrances, preservatives, cosmetic agents, among others. In the case of some antioxidant compounds, the use of high concentrations and the nature of these compounds can cause a higher exfoliation and irritation to the user skin and a discomfort sensation.

For example, the delicate region around the eyes as well as other areas of the body require special care since the skin is thinner and fragile. The skin structure in this region is different: the epidermis and dermis are thinner, thus being

more susceptible to the external aggressions and facilitating to the appearance of wrinkles and expression marks. Collagen and elastin, that contribute to a higher skin stiffness and elasticity are also present in a lower amounts that helps to characterize the delicacy of the region.

5 Hydrating agents as herein defined and useful for the present invention are those compounds or mixtures of compounds capable of increasing the water retention and restructuring the skin barrier for preventing the loss of water.

10 In a preferred way to formulate said two-phase composition, its first phase comprises an aqueous composition comprising an amount of 0.2 10%, preferably from 0.5 and 2%, of acid ascorbic and about 0.001 to 2,2%, preferably from 0.01 to 1,0%, of OPC's, particularly OPC from grape seed, and in its second phase a mixture of hydrating agents such as glycerin present at a cocentration of 1.0 to 10% and 0.5 to 3,0% of ceramides contained in a liquid crystal emulsion, also called lamellar ceramide.

15 The lamellar ceramides help to restore the skin protection barrier, thus reinforcing the skin structure and consequently preventing the excessive loss of water. Together with glycerin, which is a soft hydrating agent and that increases the retention of water by the skin, it improves the hydration and softness thereof. The high glycerin concentration also provides a high hydration potential.

20 In as still more preferred way, the two-phase composition containing antioxidants stabilized in accordance with the invention is in the form of a homogeneous emulsion comprising an emulsifying system including at least two emulsifiers, one of which is selected from the group consisting of organosilicones of the copolyol family, preferably cetyl dimethicone copolyol, and a second one the
25 molecular structure of which is similar to the natural skin lipids, preferably selected from a lipophylic stearic acid derived from a polyglycerol, more preferably polyglycerol-4-isostearate. The emulsifying system is advantageously added at a concentration of 0.5 to 8% by weight, based on the total weight of the composition.

30 In this emulsion form, the antioxidants together with the emulsifying system form micro-particles the size of which provides the emulsion with a better effectiveness and homogeneity. Since they are protected in micro-particles, the antioxidants, especially when it is OPC of grape seed, act on the walls of the blood

vessels reinforcing same, what contributes to reduce the appearance of dark rings under the eyes and avoid the formation of such dark rings. Preferably, the emulsion particles are smaller than 3 μm , more preferably smaller than 2 μm , and still more preferably smaller than 1 μm .

5 The cosmetic composition as herein described may also comprise in its second phase from 13 to 25%, preferably from about 16 to 22% of emollients, from about 1 to 4% of an anti-radical agent, more preferably from 1.5 to 3,5% of Vitamin E, from about 0.001 to 0,3% of a preservative, more preferably 0.01 to 0,3% of sodium benzoate, and from about 0.05 to 0,6% of a thickening agent, more
10 preferably from about 0.15 to 0,4% of colloidal silicon dioxide.

 It was observed that the selection of the preservative agent is an important factor for the stabilization of the emulsion micro-particles due to its stripping ratio between the water and oil phases.

 The illustrative examples and tests given below will better describe the
15 present invention. However, the illustrated data and procedures merely refer to some embodiments of the present invention and should not be understood as limiting the scope of the invention.

Example 1

 Comparative tests carried out by the inventors confirm the important
20 paper of the reverting compound in the stabilization of antioxidants as per information obtained by Wrinkler B. S. in his work cited herein. A first test was carried out in order to determine the degradation kinetics of a 10% LAA solution in water-containing medium. (m/v) under ultraviolet radiation, using a ultraviolet spectrophotometer, for 60 minutes. An immediate degradation of the LAA was
25 observed, wherein a concentration of molecular LAA of about 9,58% (m/v) remained.

 A stoichiometric amount of the reverting compound of the oxidation reaction, that is, Glutathion, was added to the previous post-irradiated solution. The resultant solution was irradiated with ultraviolet radiation for further 60 minutes. By
30 analyzing the remaining LAA, it could be noticed that 9,50% (m/v) thereof was still present. Therefore, the degradation of the LAA is dramatically minimized after the reverting compound is added.

 In a third test, a 10% LAA solution was prepared in a water-containing

medium (m/v) with a stoichiometric amount of the oxidation reaction reverting compound Glutathion. The solution was irradiated with ultraviolet radiation for 60 minutes. By analyzing the remaining LAA, a high content of 9.98% (m/v) was attained, thus confirming that the reverting compound inhibits the degradation of LAA. However, the use of said compound in stoichiometric amounts still presents the already mentioned disadvantages.

For the purpose of evaluating the invention, stability tests of the antioxidants LAA and LAA associated with OPC's in a water-containing medium have been carried out. Twelve different formulas were prepared in accordance with the invention, the chemical compositions of which as well as the obtained results are discussed in the following Tables I and II.

Table I

Formula	Glutathion (%) m/v) Reverting compound	OPC (%) m/v) Antioxidant	LAA (%) m/v) Antioxidant	Remaining LAA (%) m/v)
1	0.05	0	10	9.82
2	0.10	0	10	9.92
3	0.05	2	10	9.82
4	0.10	2	10	10.00

Table I shows the stability results of the LAA and OPC's measured by the respective remaining percentages, wherein formulas 1 through 4 have been prepared in accordance with the invention: formulas 1 and 2 including only LAA and formulas 3 and 4 comprising LAA associated with OPC's.

In the above tests, formulas 1 through 4 also comprise propylene glycol as an oxygen-removing compound, 2010 Dequest as the metallic ion sequestering agent and water.

It can be noticed from Table I that formulas 1 through 4 prepared in accordance with the invention show a LAA stability very close to 100% compared with the initial concentration.

Next, tests with further eight formulas have been carried out to evaluate

the stability of LAA plus a gelling agent (Modified Xanthane Gum). Formulas 5, 8, 11 and 12 include sodium dithionite as an oxidation reaction reverting compound, and formulas 6, 7, 9 and 10 use, again, Glutathion as the reverting compound, as shown in Table II

Table II

Formulas	Glutathion (% m/v) Reverting compound	Sodium dithionite (% m/v) Reverting compound	LAA (% m/v) Antioxidant	Remaining LAA (% m/v)
5	0.00	0.05	5.0	5.0
6	0.10	0.00	5.0	5.0
7	0.05	0.00	5.0	5.0
8	0.00	0.10	5.0	5.0
9	0.05	0.00	10.0	10.0
10	0.10	0.00	10.0	10.0
11	0.00	0.05	10.0	10.0
12	0.00	0.10	10.0	10.0

Table II shows the formulas evaluated as to stability of the LAA under ultraviolet radiation for 60 minutes. All the formulas contain propylene glycol, modified xanthane gum, Dequest 2010, PVA and water.

The purpose of the tests carried out with the compositions shown in Table II was to confirm that the stabilization of the LAA is successfully obtained with different reverting compounds.

Sodium dithionite was used in formulas 5, 8, 11 and 12, resulting in a percentage of remaining LAA of about 100% after 90 days, which means that LAA practically does not undergo any degradation during at least 90 days at room temperature, maintaining the initial concentrations of its molecular form.

The reverting compound employed in formulas 6, 7, 9 and 10 is Glutathion. From Figure 1, it can be noticed that the percentage of remaining LAA in formulas 6 and 7 remains around 100% even in the presence of another reverting compound,

Figure 2 shows the stability graph of compositions containing OPC, which is a grape seed oligomer, through which it is possible to measure the stability of said OPC.

It can be noticed that the OPC's stability under the sun light is of at least 70% and around 80% in the dark, that latter being the normal condition for the final commercial product, thus demonstrating that the result is favorable for the invention.

Example 2

A water-in-oil emulsion was prepared which comprises in a first phase:

Ingredient	% Mass	Function
Water	About 70	vehicle
Butylene glycol	1 to 4	Oxygen-removing compound
Glutathion	0.1	Oxidation reverting compound
1-Hydroethylidene (1,1-diphosphonic) acid Dequest®	0.15	Metallic ion sequestering agent
LAA	from 1 to 30	Antioxidant agent
Grape seed OPC	0.3	Antioxidant agent

and, in a second phase

Ingredient	% Mass	Function
Glycerin	7.0	Hydrating agent
Lamellar Ceramides	1.0	Hydrating agent
Cetyl dimethicone copolyol	2.0	Emulsifier
Triglycerol isostearate 4	2.0	Emulsifier
Vitamin E	2.0	Antioxidant
Sodium benzoate	0.3	Preservative
Colloidal silicon dioxide	0.3	Thickening agent
Magnesium sulphate	0.7	Thickening agent
Cyclomethicone D5/d6	13.5	Emollient
Isohexadecane	5.0	Solvent

A panel was composed in a blind study, with 80 female volunteers with ages ranging between 25 and 65 years, evaluated at two different times: after the fifteenth day of use (T15) and at the 30th day of use (T30). The product was supplied at ratios of about 16:9 of the first phase to the second phase and according to the composition described in the example above. The results of this evaluation are given in table III where the expressed percentages refer to the percentage of users that perceived the occurrence of the corresponding benefit.

Table III - Evaluation of the product performance by the physician

	T15	T30
Wrinkles	16.6%	31.2%
Flaccidity	8.7%	16.6%
Drying	11.2%	63.7%
Rings under the eyes	17.5%	27.5%
Edema	12.5%	22.5%

Amongst the product beneficial effects, including those evaluated the test, the following should be stressed out:

- it alleviated the skin aging marks around the eyes, such as wrinkles and flaccidity;
- it reduced the dark rings and pockets under the eyes;
- it improved the stiffness of the skin;

CLAIMS

1. A process for stabilizing antioxidant compounds characterized by comprising the step of contacting said compound, in an aqueous medium, with an oxygen-removing compound, a metallic ion sequestering compound and an oxidation reaction reverting
5 compound.

2. A process in accordance with claim 1, characterized in that the antioxidant compound is selected from group consisting of levogyrous ascorbic acid (LAA) and proantocianidines (OPC's)

3. A process in accordance with any one of claims 1 and 2, characterized
10 in that the antioxidant is LAA.

4. A process in accordance with claims 1 the 3, characterized in that the antioxidant comprises a further proantocianidine (OPC)

5. A process in accordance with any one of the previous claims characterized in that the oxygen-removing compound is a glycol.

6. A process in accordance with claim 5, characterized in that the
15 oxygen-removing compound is selected from propylene glycol, butylene glycol and mixtures thereof, more preferably propylene glycol.

7. A process in accordance with any one of the previous claims, characterized in that the metallic ion sequestering agent is selected from the group
20 consisting of ethylene phosphonic acids, the salts and mixtures thereof, or from the group consisting of phosphonates that include di-, tri-, tetra- and pentavalent acids, their salts and mixtures thereof.

8. A process in accordance with claim 7, characterized in that the
25 metallic ion sequestering agent is selected from the group consisting of sodium salt of 1-hydroxy ethylidene (1,1-diphosphate) acid, ethylene diamine tetra(methylenephosphonic) acid, sodium salt of ethylene diamine tetra (methylene phosphonic) acid, diethylene diamine penta(methylenephosphonic) acid, sodium salt of diethylene diamine penta (methylene phosphonic) acid, hydroxy ethylidene(1,1-diphosphate) acid and the mixtures thereof.

9. A process in accordance with claim 8, characterized in that the
30 metallic ion sequestering agent is 1-hydroxy ethylidene (1,1-diphosphate) acid.

10. A process in accordance with any one of the previous claims characterized in that the oxidation reaction reverting compound is selected from the group consisting of sodium dithionite, sodium bisulfites, calcium bisulfites, potassium bisulfites and Glutathion, as well as the mixtures thereof.

5 11. A process in accordance with claim 10, characterized in that the oxidation reaction reverting compound is Glutathion or sodium dithionite.

12. A process in accordance with any one of the previous claims, characterized by comprising a first step of preparing an aqueous solution containing the oxygen-removing compound, the metallic ion sequestering agent and the
10 oxidation reaction reverting compound, and a second stage of adding the antioxidant to the thus prepared composition, in a aqueous medium.

13. A process in accordance with claim 12, characterized in fact of the composition formed in the first step comprises the oxygen-removing compound in a range from about 10% to about 25%, the metallic ion sequestering agent in a range
15 from about 0.01% to about 0.20%, the oxidation reaction reverting compound at a concentration of about 0.01% to about 0.5%, the content of the antioxidant being from about 0.01% to about 30%, all the percentages being by weight based on the total weight of the composition.

14. A process in accordance with claim 13, characterized in fact of the
20 composition formed in the first step comprises the oxygen-removing compound in a range from about 16% to about 19%, the metallic ion sequestering agent in a range from about 0.10% to about 0.20% and the oxidation reaction reverting compound at a concentration from about 0.05% to about 0.2%, the content of the antioxidant being from about 0.5% to about 20% by weight.

25 15. A process in accordance with claim 12, characterized in that the antioxidant is an OPC, and wherein said first composition also comprises LAA.

16. An aqueous composition comprising at least one antioxidant, characterized by further comprising an oxygen-removing compound, a metallic ion sequestering agent and an oxidation reaction reverting compound.

30 17. An aqueous composition in accordance with claim 16, characterized in that the antioxidant is selected from the group consisting of levogyrous ascorbic acid (LAA) and proantocianidines (OPC's)

of an oxygen-removing compound, from about 0.01% to about 0.20 / of a metallic ion sequestering agent, and from about 0.01% to about 0.5 % of an oxidation reaction reverting compound.

28. A two-phase aqueous cosmetic composition, characterized by
5 comprising, in a first phase, at least one antioxidant, an oxygen-removing compound, a metallic ion sequestering agent and an oxidation reaction reverting compound and, in a second phase, at least one hydrating compound.

29. A two-phase composition in accordance with claim 28, characterized
10 in that the weight ratio between the first and second phases is from about 12:8 to 20:11.

30. A two-phase composition in accordance with claim 28 or 29, characterized in that said at least one antioxidant is selected from the group consisting of levogyrous ascorbic acid (LAA) and proantocianidines (OPC's).

31. A two-phase composition in accordance with any one of claims 28 to
15 30 characterized in that the oxygen-removing compound is a glycol.

32. A two-phase composition in accordance with claim 31, characterized in that the oxygen-removing compound is selected from propylene glycol, butylene glycol and the mixtures thereof, more preferably propylene glycol.

33. A two-phase composition in accordance with any one of claims 28 to
20 32, characterized in that the metallic ion sequestering agent is selected from the group consisting of ethylene phosphonic acids, the salts and mixtures thereof, or from the group consisting of phosphonates that include di-, tri-, tetra- and pentavalent acids, their salts and mixtures thereof.

34. A two-phase composition in accordance with claim 33,
25 characterized in that the metallic ion sequestering agent is selected from the group consisting of sodium salt of 1-hydroxy ethylidene (1,1-diphosphate) acid, ethylene diamine tetra(methylenephosphonic) acid, sodium salt of ethylene diamine tetra (methylene phosphonic) acid, diethylene diamine penta(methylenephosphonic) acid, sodium salt of diethylene diamine penta (methylene phosphonic) acid, hydroxy
30 ethylidene(1,1-diphosphate) acid and mixtures thereof.

35. A two-phase composition in accordance with claim 34, characterized in that the metallic ion sequestering agent is 1-hydroxy ethylidene (1,1-diphosphate)

18. An aqueous composition in accordance with any one of claims 16 and 17, characterized in that the antioxidant is LAA.

19. An aqueous composition in accordance with claims 16 the 17, characterized in that the antioxidant comprises proantocianidines (OPC's)

5 20. An aqueous composition in accordance with any one of the previous claims characterized in that the oxygen-removing compound is a glycol.

21. An aqueous composition in accordance with claim 20, characterized in that the oxygen-removing compound is selected from propylene glycol, butylene glycol and mixtures thereof, more preferably propylene glycol.

10 22. An aqueous composition in accordance with any one of the previous claims, characterized in that the metallic ion sequestering agent is selected from the group consisting of ethylene phosphonic acids, the salts and mixtures thereof, or from the group consisting of phosphonates including di-, tri-, tetra- and pentavalent acids, their salts and mixtures thereof.

15 23. An aqueous composition in accordance with claim 22, characterized in that the metallic ion sequestering agent is selected from the group consisting of sodium salt of 1-hydroxy ethylidene (1,1-diphosphate) acid, ethylene diamine tetra(methylenephosphonic) acid, sodium salt of ethylene diamine tetra (methylene phosphonic) acid, diethylene diamine penta(methylenephosphonic) acid, sodium salt of diethylene diamine penta (methylene phosphonic) acid, hydroxy ethylidene(1,1-diphosphate) acid and mixtures thereof.

24. An aqueous composition in accordance with claim 23, characterized in that the metallic ion sequestering agent is 1-hydroxy ethylidene (1,1-diphosphate) acid.

25 25. An aqueous composition in accordance with any one of the previous claims characterized in that the oxidation reaction reverting compound is selected from the group comprising sodium dithionite, sodium bissulfites, calcium bissulfites, potassium bissulfites and Glutathion, as well as mixtures thereof.

26. An aqueous composition in accordance with claim 25, characterized in that the oxidation reaction reverting compound is Glutathion or sodium dithionite.

27. An aqueous composition in accordance with claim 18, characterized by comprising from about 0.01% to about 30% of LAA, from about 10% to about 25%

acid.

36. A two-phase composition in accordance with any one of claims 28 to 35 characterized in that the oxidation reaction reverting compound is selected from the group comprising sodium dithionite, sodium bissulfites, calcium bissulfites, potassium bissulfites and Glutathion, as well as mixtures thereof.

37. An aqueous two-phase composition in accordance with claim 36, characterized in that the oxidation reaction reverting compound is Glutathion or sodium dithionite.

38. A two-phase composition in accordance with any one of claims 28 to 37, characterized in that the hydrating compound is glycerin.

39. A two-phase composition in accordance with any one of claims 28 to 37, characterized in that the second phase comprises ceramides in a liquid crystal emulsion form.

40. A two-phase composition in accordance with claim 39, characterized by comprising, in the first phase, an aqueous composition comprising an amount of 0.2 to 10% of ascorbic acid and about 0.001 to 2,2% of OPC's and, in the second phase, glycerin in a range from 1.0 to 10%, and 0.5 to 3,0% of ceramides contained in a liquid crystal emulsion, all percentages being based on the total weight of the composition.

41. A two-phase composition in accordance with any one of claims 28 to 40, characterized by further comprising, in its second phase, about 13 to 25% of emollients, about 1 to 4% of an anti-radical agent, about 0.001 to 0,3% of a preservative, and about 0.05 to 0,6% of a thickening agent.

42. A composition in accordance with any one of claims 28 to 41, characterized by being in the form of an homogeneous emulsion containing an emulsifying system comprising a first emulsifier selected from the group consisting of organosilicones and a second emulsifier having a molecular structure similar to that of skin lipids.

43. A composition in accordance with claim 42, characterized in that said organosilicone is cetyl dimethicone copolyol and the second emulsifier is polyglycerol-4-isostearate.

44. A composition in accordance with claim 42 or 43, characterized by

being in the form of micro-particles smaller than 3 μm .

45. A composition in accordance with claim 44, characterized in that the micro-particles have a size smaller than 1 μm .

INTERNATIONAL SEARCH REPORT

Int. Application No.

PCT/BR 00/00078

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K7/48 C09K15/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C09K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, PAJ, FSTA, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 846 996 A (FALLICK HARRY) 8 December 1998 (1998-12-08)	1-3, 5, 10, 11, 16-18, 20, 25, 26 28
A	column 3, line 4 -column 4, line 10	
X	US 5 023 235 A (N GUYEN QUANG L ET AL) 11 June 1991 (1991-06-11)	1-3, 10, 11, 16-18, 25, 26 28
A	column 1, line 60 -column 2, line 35 -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

14 November 2000

Date of mailing of the international search report

01/12/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040. Tx. 31 651 epo nl.
Fax (+31-70) 340-3016

Authorized officer

Shade, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/BR 00/00078

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WINKLER, BARRY S.: "Unequivocal evidence in support of the nonenzymic redox coupling between glutathione/glutathione disulfide and ascorbic acid/dehydroascorbic acid" BIOCHIM. BIOPHYS. ACTA (1992), 1117(3), 287-90, XP002152766 cited in the application	1-3,5,6, 10,11, 16-18, 20,21, 25,26
A	page 288, column 1 -column 2	28
Y	WO 99 07362 A (COSMETICOS NATURAL IND COM) 18 February 1999 (1999-02-18) cited in the application	1-3,5,6, 10,11, 16-18, 20,21, 25,26
A	page 11, line 5 -page 16, line 2	28
A	US 5 140 043 A (PINNELL SHELDON R ET AL) 18 August 1992 (1992-08-18) column 3, line 18 -column 4, line 6	1,16,28
A	WO 96 07396 A (JOHNSON & JOHNSON CONSUMER ;JOHNSON & JOHNSON MEDICAL K K (JP); LI) 14 March 1996 (1996-03-14) examples 1,12	1,16,28
A	DATABASE WPI Section Ch, Week 199525 Derwent Publications Ltd., London, GB; Class B05, AN 1995-190139 XP002152767 & JP 07 107938 A (SANEIGEN FFI KK), 25 April 1995 (1995-04-25) abstract	28

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/BR 00/00078 210

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5846996 A	08-12-1998	US 5945447 A	31-08-1999
US 5023235 A	11-06-1991	FR 2610626 A	12-08-1988
		DE 3870001 A	21-05-1992
		DE 280606 T	11-05-1989
		EP 0280606 A	31-08-1988
		JP 63225689 A	20-09-1988
WO 9907362 A	18-02-1999	BR 9704418 A	30-03-1999
		BR 9704728 A	06-06-2000
		EP 0949919 A	20-10-1999
		US 6037481 A	14-03-2000
US 5140043 A	18-08-1992	AT 156355 T	15-08-1997
		AU 647699 B	24-03-1994
		AU 5523990 A	16-11-1990
		CA 2054189 A	18-10-1990
		DE 69031219 D	11-09-1997
		DE 69031219 T	22-01-1998
		DK 486499 T	16-03-1998
		EP 0486499 A	27-05-1992
		ES 2104605 T	16-10-1997
		HK 1001834 A	10-07-1998
		JP 4507089 T	10-12-1992
		WO 9012572 A	01-11-1990
WO 9607396 A	14-03-1996	AU 3633295 A	27-03-1996
		JP 8193019 A	30-07-1996
		US 6080393 A	27-06-2000
JP 7107938 A	25-04-1995	NONE	



THIS PAGE BLANK (USPTO)